Kurs
-0,16%
Kurs
-0,16%
Open
217,99
High
217,99
Low
212,02
Close
216,61
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
3,47 MNOK
Likviditet
3,47 MNOK
Rel. mcap
5,04%
Antal aktier
16 088
Likviditet under dagen för detta pressmeddelande
Kalender
Est. tid* | ||
2026-02-19 | 22:00 | Bokslutskommuniké 2025 |
2025-11-19 | 22:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 22:00 | Kvartalsrapport 2025-Q2 |
2025-06-26 | N/A | Årsstämma |
2025-05-21 | N/A | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2025-05-21 | 22:00 | Kvartalsrapport 2025-Q1 |
2025-02-26 | - | Bokslutskommuniké 2024 |
2024-11-13 | - | Kvartalsrapport 2024-Q3 |
2024-10-10 | - | Extra Bolagsstämma 2024 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | Split BGBIO 100:1 |
2024-05-29 | - | Kvartalsrapport 2024-Q1 |
2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2024-05-23 | - | Årsstämma |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-11-14 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-06-22 | - | Kvartalsrapport 2023-Q1 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-15 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-24 | - | Kvartalsrapport 2022-Q1 |
2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-02-16 | - | Bokslutskommuniké 2021 |
2022-01-06 | - | Extra Bolagsstämma 2022 |
2021-11-16 | - | Kvartalsrapport 2021-Q3 |
2021-08-17 | - | Kvartalsrapport 2021-Q2 |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2021-03-19 | - | Årsstämma |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-12-09 | - | Extra Bolagsstämma 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-05-19 | - | Kvartalsrapport 2020-Q1 |
2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2020-03-16 | - | Årsstämma |
2020-02-11 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Kvartalsrapport 2019-Q2 |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2019-03-13 | - | Årsstämma |
2019-02-19 | - | Bokslutskommuniké 2018 |
2018-11-13 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2018-05-15 | - | Kvartalsrapport 2018-Q1 |
2018-05-14 | - | Årsstämma |
2018-03-09 | - | Extra Bolagsstämma 2018 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | Kvartalsrapport 2017-Q1 |
2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2017-03-22 | - | Årsstämma |
2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2016-06-21 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-12-13 15:00:10
Bergen, Norway, 13 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE:
BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
AXL kinase inhibitors for severe unmet medical needs, is pleased to announce
that it is presenting updated data from the Company's Phase II study of
bemcentinib (BCBC003) in a poster presentation today at the 63rd Annual American
Society of Hematology (ASH) Meeting.
Professor Sonja Loges will provide an update from the Company's Phase II study
(BGBC003) of bemcentinib in combination with low dose cytarabine (LDAC) in
older, relapsed and refractory AML patients unfit for intensive chemotherapy.
The data presented indicate that bemcentinib in combination with LDAC is well
tolerated and offers meaningful clinical benefits. Translational research has
identified immune-based activity associated with response to treatment,
demonstrating that bemcentinib elicits activation of CD8+ T cells and B
cells/plasma cells, two major adaptive immune cell populations responsible for
anti-AML immune responses. Survival data measured as median Overall Survival
(mOS) in older unfit relapsed AML patients looks encouraging compared to
historical controls all through not yet matured.
Professor Sonja Loges, Chief Investigator of the BGBC003 trial commented: "The
data on relapsed AML patients who currently have very few treatment options, is
very encouraging. These results affirm our belief that the combination of
bemcentinib and LDAC provides meaningful clinical benefits."
Details of the presentation:
Title: Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine
Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from
the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results
indicating Bemcentinib elicits anti-AML immune responses.
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding
Transplantation and Cellular Immunotherapies: Poster III
Time, Location: 6.00 - 8.00 PM Eastern, Georgia World Congress Center, Hall B5
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.